Molecular Genetics and Metabolism Reports (Mar 2016)

Successful intrauterine treatment of a patient with cobalamin C defect

  • Friedrich K. Trefz,
  • Dagmar Scheible,
  • Georg Frauendienst-Egger,
  • Martina Huemer,
  • Terttu Suomala,
  • Brian Fowler,
  • Dorothea Haas,
  • Matthias R. Baumgartner

DOI
https://doi.org/10.1016/j.ymgmr.2016.01.005
Journal volume & issue
Vol. 6, no. C
pp. 55 – 59

Abstract

Read online

Cobalamin C (cblC) defect is an inherited autosomal recessive disorder that affects cobalamin metabolism. Patients are treated with hydroxycobalamin to ameliorate the clinical features of early-onset disease and prevent clinical symptoms in late-onset disease. Here we describe a patient in whom prenatal maternal treatment with 30 mg/week hydroxycobalamin and 5 mg/day folic acid from week 15 of pregnancy prevented disease manifestation in a girl who is now 11 years old with normal IQ and only mild ophthalmic findings. The affected older sister received postnatal treatment only and is severely intellectually disabled with severe ophthalmic symptoms. This case highlights the potential of early, high-dose intrauterine treatment in a fetus affected by the cblC defect.

Keywords